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 This diploma thesis deals with an optimization of UHPSFC method for 
determination of atomoxetine and its impurities mandelic acid, o-cresol, phenol, 
phenoxyatomoxetine, benzylatomoxetine and atomoxetine carbamate. Atomoxetine is 
used as centrally acting sympathomimetic agent for the treatment of hyperkinetic 
disorders such as Attention Deficit Hyperactivity Disorder (ADHD). 
 Measurements were carried out on the UHPSFC system Aquity UPC2 with PDA 
detector and Torus Diol 1.7 µm (3.0 x 100 mm) column. ABPR pressure was optimized 
at 2000 psi and the column temperature at 40°C. Flow rate of mobile phase was 1.5 
ml/min. Additional optimization parameters were the mobile phase composition, 
gradient elution conditions (initial composition of mobile phase, gradient slope, gradient 
time, gradient curves) and the effect of analysis time on the resolution of critical peak 
pairs. PDA detector parameters were examined, including comparison of data 
acquisition in 3 D and 2 D mode, selection of detection wavelength, resolution, 
sampling rate, filter time constant and mode selected for data acquisition, in order to 
obtain the maximum sensitivity of the method. 
 Optimal conditions for the impurity profiling in the drug substance atomoxetine 
were chosen as folows: CO2/MeOH + 0.1% NH4 OH as mobile phase with a gradient 
from 1% to 40% in 14 minutes. Detection was made in the 3 D of compensated mode 
at 215 nm with a resolution of 4.8, with a sampling rate of 20 points /sec, the filtering 
time constant in the normal mode during a 15 minute analysis. The method was 
validated properly including SST (retention time, peak area, resolution, peak symmetry, 
peak width at half height) and determination of parameters of precision, accuracy, 
linearity, selectivity and robustness of the method. 
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